Published on : May 26, 2016
ALBANY, New York, May 26, 2016 : A recent research report on the global viral infections market has been added to the repository of ResearchMoz.us. The report, titled “Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics,” explores the various therapeutic options existing in the global market for the prevention and treatment of viral infections. With the help of primary and secondary research methods, the report offers a projection of the size and valuation of the market by 2021. The global viral infections market is estimated to expand at a CAGR of 6.8% between 2014 and 2021. The overall market was worth US$74.0 bn in 2014 and is anticipated to reach a valuation of US$117.6 bn by 2021. Profiles of some of the key players in the global viral infections market have been included in the report, along with the analysis of pipeline drugs developed by the market players.
Viral infections are difficult to treat as viruses reside inside our body cells. Antibiotic drugs are not effective against viral infections as they move through the blood stream and cannot penetrate body cells. Treatment and prevention techniques for viral infections include vaccines and antiviral agents.
The report discusses a number of viral infections such as human immunodeficiency virus (HIV), hepatitis C, hepatitis B, and influenza, along with their symptoms, co-morbidities, complications, and epidemiology. Information about marketed products for viral infections has been included in the report. For HIV, drugs such as Atripla, Truvada, Tivicay, Stribild, Genvoya, and Triumeq are available in the global viral infections market. Olysio, Zepatier, Sovaldi, and Harvoni are the common drugs available for the treatment of hepatitis C virus. Tamiflu developed by Roche is widely prescribed to treat influenza.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=716911?
The report analyzes pipeline drugs by stage of development and molecule type. Discussing clinical trials conducted by market players to test the pipeline drugs, the report focuses on parameters such as trial duration, failure rates, and trial size. Some of the key pipeline products in the global viral infections market are Descovy (Gilead), V-212 (Merck), Cobicistat (Johnson & Johnson), and Beclabuvir hydrochloride (Bristol-Myers Squibb).
Describing the competitive landscape, the report profiles some of the key players in the global viral infections market such as GlaxoSmithKline, Johnson & Johnson, Merck, Bristol-Myers Squibb, and Gilead Sciences. The report analyzes the revenue and market share of each of the players. While the revenue of Bristol-Myers Squibb is expected to be marginalized by 2021 due to patent expirations, the demand for drugs Tivicay and Triumeq developed by GlaxoSmithKline is expected to boost the growth of the company. Johnson & Johnson’s share in the market is anticipated to dwindle due to the declining sales of Olysio and Prezista. The report further discusses the strategic consolidations among the key players.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org